Nicotinamide Mononucleotide (NMN) is a direct precursor to NAD+, a critical coenzyme for cellular energy production (ATP) and DNA repair that declines significantly with age. Liposomal encapsulation is a delivery technology that encases NMN in a lipid sphere to protect it from degradation in the digestive system, aiming to significantly increase its absorption and bioavailability compared to standard NMN powder.
Verdict
A promising but unproven method to boost NAD+ with enhanced bioavailability.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
Low
EVIDENCE GRADE
B
MONTHLY COST
$50 - $120
Protocol
- Typical daily doses range from 100mg to 500mg, taken orally, often in the morning.
- The liposomal formulation is intended to increase bioavailability, often allowing for lower doses than standard NMN.
- Some protocols suggest co-administration with a sirtuin activator like resveratrol or pterostilbene.
Flags
- Liposomal delivery may significantly alter pharmacokinetics and required dosage compared to standard NMN.
- In late 2022, the US FDA ruled that NMN cannot be marketed as a dietary supplement, though it remains widely available.
- Long-term effects and safety in humans are not yet established.
- Quality and dosage can vary significantly between manufacturers; third-party testing is recommended.